RE:RE:James still owns MerusOK that is why many of us bought in. However, who is selling this company to the analysts and fund managers? If it was anybody on that conference call , no one will get excited about the opportunities here. Let's say TD is right and sometime in 2018 they are debt free. Say the margins do increase by 5% average and they start generating $10-20 mil profit per quarter with a 10% top line growth rate. Based on 100 million shares what's that worth. Maybe $3.25-$4.00? Who is talking about that? Who is pointing out that while all the other pharma company's are heading south MSL is going North? if your talking a triple plus on a tightly held company over the next two years, value investors could be all over this but someone has to sell them on why MSL is so different and bulletproof over the long hall.
VRX is killing this market. It is on it"s way to $10.00 by May 2017 and although I have not checked the short position I'm sure your going to see escalation there. The focus needs to go to GUD or others who have grown in an impossible market due to their niche.
It's frustrating to watch and hard on the pocket book.
JMHO